Document Detail

Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation.
MedLine Citation:
PMID:  12381234     Owner:  NLM     Status:  MEDLINE    
Evidence-based management of acute coronary syndromes (ACS) without persistent ST segment elevation involves a rational, stepwise approach to the selection of therapies with potential benefit for elderly patients. Specifically, in elderly patients with ACS without persistent ST segment elevation, therapy should be administered based on the likelihood of unstable angina or non-ST elevation myocardial infarction being present and the risks and benefits of each individual therapy. All elderly patients with suspected ACS should receive anti-ischaemic therapy consisting of beta-blockers and nitrates, and antiplatelet therapy with aspirin unless clear contraindications exist. For patients with a moderate likelihood of ACS being present, defined as prior coronary disease or recurrent pain despite the use of anti-ischaemic therapies, unfractionated heparin or enoxaparin should be added to aspirin for more intense anticoagulation. In patients with high-risk clinical features, defined as ischaemic electrocardiographic changes and positive cardiac markers such as troponins, therapy with clopidogrel or glycoprotein IIb/IIIa inhibitors should be considered in addition to aspirin and heparin. Furthermore, high-risk patients should be managed with an early invasive strategy that includes prompt cardiac catheterisation within 24 to 48 hours and appropriate use of revascularisation as determined by the findings of the catheterisation. An evidence-based approach to the treatment of elderly patients with ACS without persistent ST segment elevation will help to improve the use of beneficial therapies and interventions that are recommended by current practice guidelines.
Manesh R Patel; Matthew T Roe
Related Documents :
20014984 - Recent advances in cardiology.
15619614 - Reducing cardiac events after acute coronary syndromes.
8018004 - Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thr...
16565564 - Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarc...
20831664 - Mokken scaling of the myocardial infarction dimensional assessment scale (midas).
20334874 - Functional atrioventricular conduction block in an elderly patient with acquired long q...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  19     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2002  
Date Detail:
Created Date:  2002-10-16     Completed Date:  2002-11-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  633-46     Citation Subset:  IM    
Duke University Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Administration, Oral
Adrenergic beta-Antagonists / therapeutic use
Clinical Trials as Topic
Coronary Disease / drug therapy*
Drug Therapy, Combination
Fibrinolytic Agents / therapeutic use
Injections, Intravenous
Nitrates / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Fibrinolytic Agents; 0/Nitrates; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The drive for quality care in US nursing homes in the era of the prospective payment system.
Next Document:  HIV disease and advanced age: an increasing therapeutic challenge.